EQS-News

Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants - Seite 2

 

About Bio-Gate AG
Bio-Gate AG is a medical technology company that develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coatings and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value chain, from development to approval to production. For more information, please visit www.bio-gate.de.

 

Disclaimer
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.

---

31.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

Language:	English
Company:	Bio-Gate AG
	Neumeyerstr. 28-34
	90411 Nürnberg
	Germany
Phone:	+49 (0) 911 / 47 75 23 – 100
Fax:	+49 (0) 911 / 47 75 23 – 101
E-mail:	[e-mail]
Internet:	www.bio-gate.de
ISIN:	DE000BGAG981
WKN:	BGAG98
Listed:	Regulated Unofficial Market in Berlin, Frankfurt, Munich (m:access), Stuttgart
EQS News ID:	1692375